Taldefgrobep alfa
Spinal Muscular Atrophy (SMA)
About Biohaven
Biohaven is a neuroscience-focused biopharmaceutical company with a diversified portfolio of clinical-stage and commercial assets. Following the spin-off of its migraine franchise to Pfizer in 2022, the 'New Biohaven' is advancing a next-generation pipeline targeting neurodegenerative diseases, movement disorders, and neuropsychiatric conditions. The company leverages multiple scientific platforms, including its proprietary glutamate modulation and myostatin inhibition technologies, to address complex neurological disorders with significant market potential.
View full company profileAbout Biohaven
Biohaven is a neuroscience-focused biopharmaceutical company with a diversified portfolio of clinical-stage and commercial assets. Following the spin-off of its migraine franchise to Pfizer in 2022, the 'New Biohaven' is advancing a next-generation pipeline targeting neurodegenerative diseases, movement disorders, and neuropsychiatric conditions. The company leverages multiple scientific platforms, including its proprietary glutamate modulation and myostatin inhibition technologies, to address complex neurological disorders with significant market potential.
View full company profileTherapeutic Areas
Other Spinal Muscular Atrophy (SMA) Drugs
| Drug | Company | Phase |
|---|---|---|
| Evrysdi (risdiplam) | PTC Therapeutics | Approved |
| Apitegromab (SRK-015) | Scholar Rock Holding | Phase 3 |